Global technology company Zoono Group Limited (ASX:ZNO) is pleased to announce that it has signed a new sales and distribution agreement in China. The agreement is with Guangzhou Sanchengyun Trade Co., Ltd for the sale of Zoono branded products online in China.
Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore recently spoke with experienced business writer, Tim Boreham, for his Dr Boreham's Crucible column which was published in Biotech Daily on Friday night and then reproduced in Stockhead across the weekend.
The 2018-2019 year has been a year of transition for Anatara Lifesciences (ASX:ANR), having commenced the year with a clear focus on successfully evolving into a human health company, through the pursuit of the burgeoning gastrointestinal health market.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30th June 2019.
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, presented at the Monsoon Communications Twilight Investor Briefing, yesterday evening, in Melbourne.
Anatara Lifesciences Ltd's (ASX:ANR) CEO, Steve Lydeamore will be presenting to investors at a Monsoon Communications Twilight Investor Briefing event in Melbourne next week. Investors interested in attending this presentation are invited to reach out.
Anatara Lifesciences (ASX:ANR) provides an update on the strategic evaluation of Detach(R), its non-antibiotic animal health asset which aids in the control of diarrhoeal disease in piglets (known as scour), with potential application in other livestock animals, aquaculture and companion animals.
